Biopharma Stock Updates - 12/08/20

Covid:

$MRNA (+6.5%) - Switzerland Exercises Increased Option for 7.5 Million Doses of mRNA-1273 - https://investors.modernatx.com/news-releases/news-release-details/switzerland-exercises-increased-option-75-million-doses-mrna

Data Updates:

$QURE (+0.5%) – Presented initial data from phase 3 study of Etranacogene Dezaparvovec in Hemophilia B at ASH - https://tools.eurolandir.com/tools/Pressreleases/GetPressRelease/?ID=3846830&lang=en-GB&companycode=nl-qure&v=

$AXSM (+2.2%) – Announced results from the open-label phase 2 COMET-SI trial of AXS-05 in major depressive disorder - https://axsometherapeuticsinc.gcs-web.com/news-releases/news-release-details/axsome-therapeutics-announces-positive-results-comet-si-trial?field_nir_news_date_value[min]=

$XENE (+4%) – Interim data from phase 2 study presented at AES2020 - https://investor.xenon-pharma.com/news-releases/news-release-details/xenon-pharmaceuticals-provides-updates-neurology-pipeline

$QURE (-0.4%) - Two-Year Follow-Up Data from the Phase IIb Study of Etranacogene Dezaparvovec - https://tools.eurolandir.com/tools/Pressreleases/GetPressRelease/?ID=3846649&lang=en-GB&companycode=nl-qure&v=

$QURE (-0.4%) – Five year follow up data for ongoing phase ½ of AMT-060 https://tools.eurolandir.com/tools/Pressreleases/GetPressRelease/?ID=3846649&lang=en-GB&companycode=nl-qure&v=

$FMTX (+20%) – Presented data at ASH of FT-4202 to treat Sickle Cell Disease (SCD) - https://ir.formatherapeutics.com/news-releases/news-release-details/forma-therapeutics-presents-clinical-proof-concept-data-62nd - plan to initiate phase 2/3 in Q1 2021

$GLYC (-2.5%) – Presented data for Rivipansel in Sickle Cell Acute Vaso-Occlusive Crisis at ASH - https://ir.glycomimetics.com/news-releases/news-release-details/new-supportive-efficacy-data-glycomimetics-rivipansel-sickle

$NKTR (-0.3%) – Presented data for NKTR-255 (IL-15 agonist) at ASH - https://ir.nektar.com/news-releases/news-release-details/nektar-therapeutics-announces-presentation-preclinical-data-nktr

Offerings:

$KURA (+8%) – Commence public offering - https://ir.kuraoncology.com/news-releases/news-release-details/kura-oncology-announces-commencement-public-offering-common-3

$SNDX (-6%) - Announces Proposed Public Offering - http://ir.syndax.com/news-releases/news-release-details/syndax-announces-proposed-public-offering-common-stock-1

$ARCT (-17%) - Announces Proposed Public Offering & Pricing of $110/share - https://ir.arcturusrx.com/news-releases/news-release-details/arcturus-therapeutics-announces-pricing-150-million-public

$FMTX (+20%) - Launches Proposed Public Offering - https://ir.formatherapeutics.com/news-releases/news-release-details/forma-therapeutics-launches-proposed-public-offering

0 comments